Answers are grounded in this paper and cite their sources.
Advances in genetics and biomarkers now identify individuals at risk for ALS and FTD years before symptoms emerge, creating opportunities for prevention and targeted therapies. Drawing on my family’s experience with TARDBP-associated ALS–FTD and my work as a clinical neuropsychologist, this perspective highlights gaps in genetic counseling, longitudinal monitoring, caregiver support, and life planning, emphasizing the need to align scientific advances with programs supporting at-risk individuals and families.
No takes yet. Share an insight, caveat, or question.
A. Campbell Sullivan (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: